Scientists test 'Living Drug' for Tough-to-Treat blood cancer
NCT ID NCT04795882
Summary
This early-stage trial is testing the safety of a new type of personalized cell therapy for people with advanced multiple myeloma that has stopped responding to standard treatments. Doctors will collect and genetically modify a patient's own immune cells (T cells) to help them find and attack cancer cells. The study will first determine safe dose levels and whether these modified cells can be reliably manufactured for treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University College London Hospital
RECRUITINGLondon, County (Optional), United Kingdom
Contact
Conditions
Explore the condition pages connected to this study.